Cargando…

Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil

BACKGROUND: Early detection of leprosy and multidrug therapy are crucial to achieve zero transmission and zero grade II incapacities goals of World Health Organization. Leprosy is difficult to diagnose because clinical forms vary and there are no gold standard methods to guide clinicians. The serolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Leturiondo, André Luiz, Noronha, Ariani Batista, do Nascimento, Monik Oney Oliveira, Ferreira, Cynthia de Oliveira, Rodrigues, Fabíola da Costa, Moraes, Milton Ozório, Talhari, Carolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322275/
https://www.ncbi.nlm.nih.gov/pubmed/30616580
http://dx.doi.org/10.1186/s12879-018-3653-0
_version_ 1783385588074807296
author Leturiondo, André Luiz
Noronha, Ariani Batista
do Nascimento, Monik Oney Oliveira
Ferreira, Cynthia de Oliveira
Rodrigues, Fabíola da Costa
Moraes, Milton Ozório
Talhari, Carolina
author_facet Leturiondo, André Luiz
Noronha, Ariani Batista
do Nascimento, Monik Oney Oliveira
Ferreira, Cynthia de Oliveira
Rodrigues, Fabíola da Costa
Moraes, Milton Ozório
Talhari, Carolina
author_sort Leturiondo, André Luiz
collection PubMed
description BACKGROUND: Early detection of leprosy and multidrug therapy are crucial to achieve zero transmission and zero grade II incapacities goals of World Health Organization. Leprosy is difficult to diagnose because clinical forms vary and there are no gold standard methods to guide clinicians. The serological rapid tests aid the clinical diagnosis and are available for field use. They are easy to perform, do not require special equipment or refrigeration and are cheaper than the molecular tests. METHODS: We evaluated the performance of two rapid serological tests (PGL1 and NDO-LID) in the discrimination of leprosy cases from healthy individuals at the Alfredo da Matta Foundation, a reference center for the disease in Manaus, Amazonas, Brazil. PGL1 and NDO-LID rapid tests are capable of detecting specific antibodies of M. leprae, IgM and IgM/IgG, respectively. A total of 530 healthy subjects and 171 patients (50 with paucibacillary and 121 multibacillary leprosy) were included in the study. RESULTS: Among the paucibacillary leprosy patients, the sensitivity was 34.0 and 32.0% for the NDO-LID and PGL1, respectively. In multibacillary leprosy patients, the NDO-LID sensitivity was 73.6% and the PGL1 was 81.0%. Serological tests demonstrated specificities of 75.9% for PGL-1 and 81.7% for NDO-LID. The positive predictive value (PPV), negative predictive value (NPV) and accuracy in multibacillary patients were 47.9, 93.1, and 80.2% respectively for the NDO-LID, and 43.4, 94.6 76.8% for PGL1. CONCLUSIONS: The tests showed limited capacity in the diagnosis of the disease, however, the high negative predictive value of the tests indicates a greater chance of true negatives in this group favoring exclusion of leprosy. This characteristic of the ML flow test is important in aiding clinical Diagnosis, especially in a region endemic to the disease and with other confounding skin conditions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12879-018-3653-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6322275
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63222752019-01-09 Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil Leturiondo, André Luiz Noronha, Ariani Batista do Nascimento, Monik Oney Oliveira Ferreira, Cynthia de Oliveira Rodrigues, Fabíola da Costa Moraes, Milton Ozório Talhari, Carolina BMC Infect Dis Research Article BACKGROUND: Early detection of leprosy and multidrug therapy are crucial to achieve zero transmission and zero grade II incapacities goals of World Health Organization. Leprosy is difficult to diagnose because clinical forms vary and there are no gold standard methods to guide clinicians. The serological rapid tests aid the clinical diagnosis and are available for field use. They are easy to perform, do not require special equipment or refrigeration and are cheaper than the molecular tests. METHODS: We evaluated the performance of two rapid serological tests (PGL1 and NDO-LID) in the discrimination of leprosy cases from healthy individuals at the Alfredo da Matta Foundation, a reference center for the disease in Manaus, Amazonas, Brazil. PGL1 and NDO-LID rapid tests are capable of detecting specific antibodies of M. leprae, IgM and IgM/IgG, respectively. A total of 530 healthy subjects and 171 patients (50 with paucibacillary and 121 multibacillary leprosy) were included in the study. RESULTS: Among the paucibacillary leprosy patients, the sensitivity was 34.0 and 32.0% for the NDO-LID and PGL1, respectively. In multibacillary leprosy patients, the NDO-LID sensitivity was 73.6% and the PGL1 was 81.0%. Serological tests demonstrated specificities of 75.9% for PGL-1 and 81.7% for NDO-LID. The positive predictive value (PPV), negative predictive value (NPV) and accuracy in multibacillary patients were 47.9, 93.1, and 80.2% respectively for the NDO-LID, and 43.4, 94.6 76.8% for PGL1. CONCLUSIONS: The tests showed limited capacity in the diagnosis of the disease, however, the high negative predictive value of the tests indicates a greater chance of true negatives in this group favoring exclusion of leprosy. This characteristic of the ML flow test is important in aiding clinical Diagnosis, especially in a region endemic to the disease and with other confounding skin conditions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12879-018-3653-0) contains supplementary material, which is available to authorized users. BioMed Central 2019-01-07 /pmc/articles/PMC6322275/ /pubmed/30616580 http://dx.doi.org/10.1186/s12879-018-3653-0 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Leturiondo, André Luiz
Noronha, Ariani Batista
do Nascimento, Monik Oney Oliveira
Ferreira, Cynthia de Oliveira
Rodrigues, Fabíola da Costa
Moraes, Milton Ozório
Talhari, Carolina
Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil
title Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil
title_full Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil
title_fullStr Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil
title_full_unstemmed Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil
title_short Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil
title_sort performance of serological tests pgl1 and ndo-lid in the diagnosis of leprosy in a reference center in brazil
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322275/
https://www.ncbi.nlm.nih.gov/pubmed/30616580
http://dx.doi.org/10.1186/s12879-018-3653-0
work_keys_str_mv AT leturiondoandreluiz performanceofserologicaltestspgl1andndolidinthediagnosisofleprosyinareferencecenterinbrazil
AT noronhaarianibatista performanceofserologicaltestspgl1andndolidinthediagnosisofleprosyinareferencecenterinbrazil
AT donascimentomonikoneyoliveira performanceofserologicaltestspgl1andndolidinthediagnosisofleprosyinareferencecenterinbrazil
AT ferreiracynthiadeoliveira performanceofserologicaltestspgl1andndolidinthediagnosisofleprosyinareferencecenterinbrazil
AT rodriguesfabioladacosta performanceofserologicaltestspgl1andndolidinthediagnosisofleprosyinareferencecenterinbrazil
AT moraesmiltonozorio performanceofserologicaltestspgl1andndolidinthediagnosisofleprosyinareferencecenterinbrazil
AT talharicarolina performanceofserologicaltestspgl1andndolidinthediagnosisofleprosyinareferencecenterinbrazil